These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18767942)

  • 1. Immunotherapy for HCV infection: next steps.
    Lang K; Weiner DB
    Expert Rev Vaccines; 2008 Sep; 7(7):915-23. PubMed ID: 18767942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-based therapy for chronic hepatitis C.
    Chang DY; Shin EC
    J Leukoc Biol; 2009 Jul; 86(1):33-9. PubMed ID: 19395471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.
    Lauer GM
    J Infect Dis; 2013 Mar; 207 Suppl 1():S7-S12. PubMed ID: 23390305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of prophylactic and therapeutic vaccines against hepatitis C virus.
    Leroux-Roels G
    Expert Rev Vaccines; 2005 Jun; 4(3):351-71. PubMed ID: 16026249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hepatitis C in patients who have decompensated cirrhosis.
    Everson GT
    Clin Liver Dis; 2005 Aug; 9(3):473-86, viii. PubMed ID: 16023978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys.
    Park SH; Lee SR; Hyun BH; Kim BM; Sung YC
    Vaccine; 2008 Jul; 26(32):3978-83. PubMed ID: 18556097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subversion of innate host antiviral strategies by the hepatitis C virus.
    Bode JG; Brenndörfer ED; Häussinger D
    Arch Biochem Biophys; 2007 Jun; 462(2):254-65. PubMed ID: 17467654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of the novel oral vaccine against hepatitis C virus utilizing bifidobacteria].
    Shirakawa T
    Nihon Rinsho; 2015 Feb; 73(2):239-42. PubMed ID: 25764677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hepatitis C crisis.
    St John TM; Sandt L
    Ethn Dis; 2005; 15(2 Suppl 2):S52-7. PubMed ID: 15822840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute hepatitis C: prevention and treatment.
    Ozaras R; Tahan V
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):351-61. PubMed ID: 19344247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for a vaccine against the hepatitis C virus.
    Houghton M; Abrignani S
    Nature; 2005 Aug; 436(7053):961-6. PubMed ID: 16107836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis.
    Sato Y; Oya H; Yamamoto S; Kobayashi T; Watanabe T; Kokai H; Yamagiwa S; Hatakeyama K
    Hepatogastroenterology; 2009; 56(89):205-7. PubMed ID: 19453058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Virus C hepatitis: successful therapy in a health care worker].
    Fantini S; Zarelli L; Tomao P; Vonesch N; Signorini S; Martini A
    G Ital Med Lav Ergon; 2007; 29(3 Suppl):763-4. PubMed ID: 18409947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles.
    Pham TN; Mercer SE; Michalak TI
    J Viral Hepat; 2009 Aug; 16(8):547-56. PubMed ID: 19215578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and vaccination for hepatitis C: present and future.
    Jawaid A; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental models for hepatitis C viral infection.
    Boonstra A; van der Laan LJ; Vanwolleghem T; Janssen HL
    Hepatology; 2009 Nov; 50(5):1646-55. PubMed ID: 19670425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.